Investigational drug · Phase 3
B001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neuromyelitis Optica Spectrum Disorders.
Phase 3Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
19
Any phase or sponsor naming "B001"
First trial start
2024
Jul 17, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B001", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Neuromyelitis Optica Spectrum Disorders
Largest trials
Live from ClinicalTrials.gov: studies naming "B001" as an intervention, largest first.
- A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaPivotal-lookingActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05943795 · 589 participants · Start Jul 14, 2023 · Primary completion Jul 2026
Drug: SI-B001; Docetaxel · For: Non-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lung
Sites: Guangzhou, China; Hangzhou, China
- Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)Pivotal-lookingStatus unknown
Cairo UniversityAcademic, hospital or other
NCT04571437 · 204 participants (planned) · Start Mar 1, 2020 · Primary completion Oct 31, 2021
Drug: Capecitabine; Letrozole 2.5mg · For: Breast Cancer; Estrogen Receptor-positive Breast Cancer; Metastatic Breast Cancer
Sites: Cairo, Egypt
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)Pivotal-lookingRecruiting
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT06413654 · 132 participants (planned) · Start Jul 17, 2024 · Primary completion Oct 31, 2027
Drug: B001 · For: Neuromyelitis Optica Spectrum Disorders
Sites: Beijing, China; Cangzhou, China; Changsha, China · 51 sites in all
- A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05949606 · 95 participants · Start Oct 30, 2023 · Primary completion Dec 2026
Drug: SI-B001; SI-B003 · For: Non-small Cell Lung Cancer
Sites: Shanghai, China
University of DhakaAcademic, hospital or other
NCT01589445 · 77 participants · Start Nov 2008 · Primary completion Dec 2009
Drug: Pioglitazone hydrochloride; Metformin hydrochloride · For: Type 2 Diabetes Mellitus
Sites: Dhaka, Bangladesh
- A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible UrticariaRecruiting
Granular Therapeutics LimitedIndustry
NCT07181369 · 72 participants (planned) · Start Oct 6, 2025 · Primary completion Aug 2027
Drug: GTX-B001; Normal Saline · For: Healthy Subjects; Cold Urticaria; Symptomatic Dermographism and 1 more
Sites: Berlin, Germany; Halle, Germany; Marburg, Germany · 6 sites in all
- A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05668858 · 70 participants · Start Feb 10, 2023 · Primary completion Dec 2026
Drug: SI-B001; SI-B003 · For: Squamous Cell Carcinoma of Head and Neck
Sites: Shanghai, China
- SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.Active, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05020457 · 69 participants · Start Dec 7, 2021 · Primary completion Dec 2025
Drug: SI-B001; AP or TP and 1 more · For: Non Small Cell Lung Cancer
Sites: Chongqing, China; Guangzhou, China; Guilin, China · 6 sites in all
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT04603287 · 60 participants · Start Apr 17, 2020 · Primary completion Dec 2025
Drug: SI-B001 · For: Locally Advanced or Metastatic Epithelial Tumor
Sites: Guangzhou, China; Chengdu, China; Hangzhou, China
International AIDS Vaccine InitiativeResearch network
NCT00851383 · 56 participants · Start Mar 2009 · Primary completion Aug 2011
Drug: Ad35-GRIN/ENV; Ad35-GRIN · For: HIV; HIV Infections
Sites: Rochester, New York
Newest research
PubMed records naming it or its code names, newest first.
- BoOFP6 Negatively Regulates Glucosinolates Accumulation in Broccoli Sprouts by Cytoplasmic Sequestration of BoMYB34-3.
Niu M, Guo Y, Zhao Y, et al. · Plant Cell Environ 2026
- Distinct pro-inflammatory responses to pristine and microbially contaminated PET nanoplastics in a human alveolar cell co-culture.
Haugen ØP, Sagen AS, Barbero F, et al. · Front Toxicol 2026
- A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.
Jia D, Wang H, Jiang W, et al. · Front Immunol 2026
- Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.
Xue J, Ma Y, Zhao Y, et al. · Clin Cancer Res 2025
- Phosphate modified nanoarchitectonics for promoted photocatalytic singlet oxygen generation and carbamazepine degradation of (010) facet-exposed BiOCl.
Xu H, Cao L, Yu Y, et al. · J Colloid Interface Sci 2025
- Structure-based virtual screening and fragment replacement to design novel inhibitors of Coxsackievirus A16 (CVA16).
Zhou J, Zhao Y, Yang R, et al. · J Biomol Struct Dyn 2024
Also in development for Neuromyelitis Optica Spectrum Disorders
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- divozilimabPhase 32 trials
Biocad · Neuromyelitis Optica Spectrum Disorders, Systemic Scleroderma
- JYP0061Experimental Drug GroupPhase 22 trials
Guangzhou JOYO Pharma Co., Ltd · Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.